Biomarker test company Cleveland HeartLab made a splash recently at TEDMED, with about 500 conference-goers taking the company’s heart inflammation tests.
Results of the TEDMED tests showed that 41 percent of those who submitted samples had high cholesterol or low HDL (good cholesterol), 28 percent showed evidence of hardening of the arteries and 12 percent tested positive for plaque in the arteries.
Cleveland HeartLab founder and chief science officer Dr. Marc Penn presented the results on stage at TEDMED.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
“We’re looking at classic risk factors like lipids,” Penn said. “We’re also looking at inflammatory markers that not only define whether you have hardening of the artery, but also define whether your artery is active and at-risk for a cardiovascular event, such as stroke or heart attack.”
Watch the video below to see Penn’s presentation.